UBS Group
COLL icon

UBS Group’s Collegium Pharmaceutical COLL Stock Holding History

UBS Group’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.46M Buy
206,070
+162,733
+376% +$5.56M ﹤0.01% 3769
2026
Q1 		$1.43M Sell
43,337
-52,550
-55% -$2.22M ﹤0.01% 5259
2025
Q4 		$4.44M Sell
95,887
-159,572
-62% -$6.68M ﹤0.01% 4153
2025
Q3 		$8.94M Buy
255,459
+24,423
+11% +$849K ﹤0.01% 3423
2025
Q2 		$6.83M Buy
231,036
+14,505
+7% +$414K ﹤0.01% 3537
2025
Q1 		$6.46M Buy
216,531
+16,014
+8% +$489K ﹤0.01% 3520
2024
Q4 		$5.74M Buy
200,517
+164,296
+454% +$5.44M ﹤0.01% 3678
2024
Q3 		$1.4M Buy
36,221
+12,948
+56% +$462K ﹤0.01% 4329
2024
Q2 		$749K Sell
23,273
-8,328
-26% -$289K ﹤0.01% 4676
2024
Q1 		$1.23M Buy
31,601
+28,428
+896% +$995K ﹤0.01% 4435
2023
Q4 		$97.7K Buy
3,173
+475
+18% +$11.9K ﹤0.01% 6178
2023
Q3 		$60.3K Sell
2,698
-8,798
-77% -$201K ﹤0.01% 6175
2023
Q2 		$247K Buy
11,496
+1,685
+17% +$38.3K ﹤0.01% 5343
2023
Q1 		$235K Buy
9,811
+7,816
+392% +$207K ﹤0.01% 5265
2022
Q4 		$46.3K Sell
1,995
-1,561
-44% -$31.5K ﹤0.01% 6841
2022
Q3 		$57K Buy
3,556
+2,667
+300% +$47K ﹤0.01% 6209
2022
Q2 		$16K Sell
889
-950
-52% -$16K ﹤0.01% 7183
2022
Q1 		$37K Sell
1,839
-1,263
-41% -$23.9K ﹤0.01% 6787
2021
Q4 		$58K Sell
3,102
-943
-23% -$18.4K ﹤0.01% 6762
2021
Q3 		$79K Sell
4,045
-11,846
-75% -$256K ﹤0.01% 5995
2021
Q2 		$376K Sell
15,891
-3,421
-18% -$79K ﹤0.01% 4929
2021
Q1 		$458K Buy
19,312
+3,961
+26% +$94.1K ﹤0.01% 4936
2020
Q4 		$308K Buy
15,351
+10,489
+216% +$205K ﹤0.01% 4951
2020
Q3 		$102K Sell
4,862
-14,222
-75% -$257K ﹤0.01% 5164
2020
Q2 		$334K Sell
19,084
-3,655
-16% -$71.6K ﹤0.01% 4434
2020
Q1 		$372K Sell
22,739
-27,522
-55% -$568K ﹤0.01% 4224
2019
Q4 		$1.03M Buy
50,261
+20,811
+71% +$347K ﹤0.01% 4183
2019
Q3 		$338K Buy
29,450
+26,680
+963% +$305K ﹤0.01% 4853
2019
Q2 		$36K Sell
2,770
-1,850
-40% -$24.7K ﹤0.01% 6182
2019
Q1 		$70K Sell
4,620
-3,619
-44% -$58K ﹤0.01% 5319
2018
Q4 		$141K Sell
8,239
-215
-3% -$3.68K ﹤0.01% 5235
2018
Q3 		$124K Sell
8,454
-60,564
-88% -$1.07M ﹤0.01% 5397
2018
Q2 		$1.65M Sell
69,018
-132,940
-66% -$3.27M ﹤0.01% 3339
2018
Q1 		$5.16M Buy
201,958
+51,204
+34% +$1.22M ﹤0.01% 2281
2017
Q4 		$2.78M Buy
150,754
+139,824
+1,279% +$2M ﹤0.01% 2894
2017
Q3 		$114K Sell
10,930
-10,374
-49% -$114K ﹤0.01% 5238
2017
Q2 		$267K Buy
21,304
+7,537
+55% +$74.5K ﹤0.01% 4558
2017
Q1 		$139K Buy
13,767
+10,174
+283% +$151K ﹤0.01% 4876
2016
Q4 		$56K Buy
3,593
+175
+5% +$2.91K ﹤0.01% 5729
2016
Q3 		$66K Buy
3,418
+418
+14% +$4.96K ﹤0.01% 5287
2016
Q2 		$36K Sell
3,000
-1,500
-33% -$24.8K ﹤0.01% 5774
2016
Q1 		$82K Buy
4,500
+2,208
+96% +$40.1K ﹤0.01% 5116
2015
Q4 		$63K Buy
2,292
+1,792
+358% +$37.8K ﹤0.01% 5613
2015
Q3 		$11K Buy
+500
New +$9.04K ﹤0.01% 7196

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

UBS Group's COLL Position: Q2 2026 in Review

UBS Group increased its Collegium Pharmaceutical (COLL) stake by 376% in Q2 2026, buying an estimated $5.56M and bringing the position to 206,070 shares worth $7.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3769.

UBS Group first reported a position in COLL in Q3 2015 and has held it in 44 quarters since. The position peaked at $8.94M in Q3 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • UBS Group held 206,070 shares of Collegium Pharmaceutical worth $7.46M as of Q2 2026.
  • UBS Group bought 162,733 Collegium Pharmaceutical shares in Q2 2026, an estimated $5.56M.
  • Collegium Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3769 holding.
  • UBS Group first reported a position in Collegium Pharmaceutical in Q3 2015 and has held it in 44 quarters since.
  • UBS Group's Collegium Pharmaceutical position peaked at $8.94M in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.